科伦博泰生物(06990)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06990 科伦博泰生物

未开盘 09-29 16:08:04

473.000

+17.800

+3.91%

最高479.400	最低460.600	成交量68.55万
今开465.000	昨收455.200	日振幅4.13%
总市值1,130亿	流通市值837.21亿	总股本2.39亿
成交额3.24亿	换手率0.39%	流通股本1.77亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06990","market":"HK","secType":"STK","nameCN":"科伦博泰生物","latestPrice":473,"timestamp":1790669284007,"preClose":455.2,"halted":0,"volume":685535,"delay":0,"changeRate":0.03910369068541303,"floatShares":177000000,"shares":239000000,"eps":-1.65683,"marketStatus":"未开盘","change":17.8,"latestTime":"09-29 16:08:04","open":465,"high":479.4,"low":460.6,"amount":324068436,"amplitude":0.041301,"askPrice":473,"askSize":15600,"bidPrice":472.4,"bidSize":1400,"shortable":3,"etf":0,"ttmEps":0.748354,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790731800000},"marketStatusCode":0,"adr":0,"listingDate":1689004800000,"exchange":"SEHK","adjPreClose":455.2,"openAndCloseTimeList":[[1790645400000,1790654400000],[1790658000000,1790668800000]],"volumeRatio":1.7299406523024665,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06990","defaultTab":"news","newsList":[{"id":"2671160812","title":"东方证券股份有限公司(DFZQ)增持科伦博泰生物(06990.HK)2.52万股 每股作价约490.76港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2671160812","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671160812?lang=zh_cn&edition=full","pubTime":"2026-09-29 19:16","pubTimestamp":1790680598,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06990","BK1564","LU0196878994.USD","BK1161","03958","BK1147"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181251520","title":"科伦博泰生物：东方证券增持，好仓比例升至5.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=1181251520","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181251520?lang=zh_cn&edition=full","pubTime":"2026-09-29 17:14","pubTimestamp":1790673264,"startTime":"0","endTime":"0","summary":"东方证券股份有限公司（DFZQ）于2026年9月22日在联交所场内以每股均价490.7615港元买入四川科伦博泰生物医药股份有限公司（科伦博泰生物，06990）H股2.52万股，涉资约1236.72万港元，属场内主动交易，即在二级市场直接买卖股份。东方证券此次增持前持有科伦博泰生物好仓881.94万股，占比4.98%；增持后持股量为884.46万股，好仓比例升至5.0%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671293354","title":"创新药概念股逆市走强 康方生物（09926）涨16.85%、康诺亚-B（02162）涨10.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2671293354","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671293354?lang=zh_cn&edition=full","pubTime":"2026-09-29 13:20","pubTimestamp":1790659249,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念股逆市走强，康方生物 涨16.85%，康诺亚-B涨10.32%，乐普生物涨7.88%，荣昌生物涨5.41%，科伦博泰生物涨5.32%，博安生物涨4.74%，恒瑞医药涨4.02%，再鼎医药涨4.02%。根据Insight数据，除已经在美国获批上市的药物外，已达成出海合作的国产创新药中有27款处于临床后期。其中，依沃西单抗、匹米替尼已在美国申请上市，芦康沙妥珠单抗、伦康依隆妥单抗、SSGJ-707等重点品种处于临床III期。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992749","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU1023057109.AUD","BK1587","BK1191","IE00BPRC5H50.USD","LU2476274308.USD","IBBQ","06955","LU0348827113.USD","LU0417516902.SGD","LU1961090484.USD","LU2488822045.USD","02162","MEDX","KURE","09926","LU1720050803.USD","159992","LU0417516738.SGD","BK1583","LU0561508036.HKD","06978","LU2543165471.USD","02157","BK1588","LU1969619763.USD","LU2476274720.SGD","09995","LU0359201885.HKD","LU0196878994.USD","LU2328871848.SGD","LU0348766576.USD","LU2778985437.USD","LU0348735423.USD","LU0348767384.USD","BK1574","LU0359201612.USD","LU0417516571.SGD","IE00B5MMRT66.SGD","09688","LNGR","LU0348784397.USD","LU0359202008.SGD","LU1794554557.SGD","01276","06990","LU0348825331.USD","LU0634319403.HKD","IE00B543WZ88.USD","LU0348783233.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118312838","title":"异动解读｜科伦博泰生物盘中上涨4.17%，芦康沙妥珠单抗多项研究入选ESMO大会LBA叠加板块共振","url":"https://stock-news.laohu8.com/highlight/detail?id=1118312838","media":"行情直击","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118312838?lang=zh_cn&edition=full","pubTime":"2026-09-29 10:07","pubTimestamp":1790647640,"startTime":"0","endTime":"0","summary":"9月29日，科伦博泰生物盘中上涨4.17%，报474.2港元，成交额8935.05万港元。消息面上，公司近日公告自主研发的TROP2 ADC芦康沙妥珠单抗多项III期临床研究入选即将于10月举行的欧洲肿瘤内科学会大会最新突破性摘要，并将以口头报告形式呈现。同时，生物科技板块今日整体走强，康方生物涨12.17%、康诺亚-B涨7.66%，形成板块共振。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"科伦博泰生物上涨，芦康沙妥珠单抗入选ESMO大会LBA","news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669467248","title":"汇添富基金管理股份有限公司增持科伦博泰(06990.HK)2.52万股 每股作价约490.76港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2669467248","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669467248?lang=zh_cn&edition=full","pubTime":"2026-09-24 19:28","pubTimestamp":1790249303,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06990","BK1161","LU0196878994.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669451177","title":"生物医药板块全线走低 诺诚健华（09969）跌10.48% 机构指行业需求尚未明显回暖","url":"https://stock-news.laohu8.com/highlight/detail?id=2669451177","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669451177?lang=zh_cn&edition=full","pubTime":"2026-09-24 13:36","pubTimestamp":1790228201,"startTime":"0","endTime":"0","summary":"金吾财讯 |  港股生物医药板块午后全线走低，截至发稿，诺诚健华 跌10.48%，荣昌生物跌7.99%，复宏汉霖跌7.68%，康诺亚-B跌5.86%，再鼎医药跌5.32%，君实生物跌4.53%，金斯瑞生物科技跌4.21%，康方生物跌3.54%，科伦博泰生物跌3.11%，泰格医药跌2.35%，药明生物跌1.80%，百济神州跌1.56%，药明合联跌1.12%。消息面上，国盛证券发布研报称，医药行业需求尚未明显回暖，降本增效、费用精细化管理已成为利润端的重要支撑。下半年关注流感旺季带来的阶段性需求催化。","market":"other","thumbnail":"https://static.szfiu.com/news/20210810/ZTUyNTQ0NjcxODUwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZTUyNTQ0NjcxODUwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992441","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548","LU0828237510.HKD","LU0348825331.USD","161726","09995","LU1961090484.USD","BK1141","09926","02696","02268","09688","399441","BK1576","688428","KURE","LU0856984785.SGD","LU2328871848.SGD","LU3063872942.SGD","SG9999002562.SGD","LU0516422366.SGD","LU0561508036.HKD","BK4581","LU2039709279.SGD","LU0348783233.USD","LU2399975544.HKD","LU1242518931.SGD","SG9999014674.SGD","01877","02269","LU0456846285.SGD","03347","LU1242518857.USD","XBI","LU0540923850.HKD","BK1515","HK0000306701.USD","02162","LU1770034418.SGD","06160","09969","LU1303224171.USD","LU1719994722.HKD","BK1583","LU0516423174.USD","LU0140636845.USD","LU0348766576.USD","LU1880383366.USD","SG9999002463.SGD","06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669535961","title":"花旗：医药工业发展“十五五”规划利好创新药及医疗器械 首选石药集团(01093)等","url":"https://stock-news.laohu8.com/highlight/detail?id=2669535961","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669535961?lang=zh_cn&edition=full","pubTime":"2026-09-21 15:03","pubTimestamp":1789974221,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，花旗发布研报称，工信部等部门联合发布《医药工业发展“十五五”规划》，核心是推动中国医药工业由规模驱动增长转向创新驱动、质量导向发展，并明确提出到2030年跻身世界领先行列的目标。规划涵盖创新药、创新医疗器械、人工智能驱动药物发现，以及CDMO/CRO等技术领域，显示政策正对整条价值链作出广泛支持。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1498647.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IEIH","HART","HK0000165453.HKD","LU0561508036.HKD","LU1244550494.USD","IYF","LU0029874905.USD","LU1152091168.USD","BK4566","LU0029874061.USD","03347","01276","BK1576","LU0456827905.SGD","LU1226287875.USD","MEDX","LU1242518931.SGD","SG9999002463.SGD","LU0516422366.SGD","LU1366192091.USD","06990","KURE","PTH","02269","BK4588","MDEV","TFNS","IE00B543WZ88.USD","LGHT","FTXO","09996","159992","LU0128525689.USD","01093","06978","GDOC","LU1242518857.USD","LNGR","01801","LU2417539215.USD","AGNG","IBBQ","LU0516422440.USD","159883","LU3063872942.SGD","LU0067412154.USD","LU1807302812.USD","LU0359201885.HKD","LU0455707207.USD","RSPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669549132","title":"港股午盘｜恒指涨0.56% 创新药概念股走强","url":"https://stock-news.laohu8.com/highlight/detail?id=2669549132","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669549132?lang=zh_cn&edition=full","pubTime":"2026-09-21 12:04","pubTimestamp":1789963446,"startTime":"0","endTime":"0","summary":"恒指涨0.56%，恒生科技指数跌0.13%，创新药概念股走强，康方生物涨近9%，科伦博泰生物涨近8%，三生制药涨逾6%。黄金股普跌，中国黄金国际跌逾7%，灵宝黄金跌近5%，山东黄金、紫金黄金国际跌逾3%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://stock.eastmoney.com/a/202609213879859453.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.eastmoney.com/a/202609213879859453.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["HSTECH","LU0196878994.USD","BK1583","LU0417516738.SGD","LU0417516571.SGD","BK1593","LU1720050803.USD","02833","03037","03419","LU2543165471.USD","HK0000252160.HKD","LU2213484517.USD","82800","SGXZ86797644.SGD","LU2476274308.USD","01787","07200","01530","HHImain","LU0348784397.USD","02800","07500","513600","LU2039709279.SGD","LU2399975544.HKD","06990","BK1574","LU0634319403.HKD","LU0979878070.USD","600547","JINFF","LU1813983027.USD","LU2488822045.USD","LU0463099449.HKD","KURE","09115","BK1198","LU1242518931.SGD","LU0326950275.SGD","HK0000252152.HKD","02099","LU1961090484.USD","LU2476274720.SGD","LU1188198961.HKD","LU0348827113.USD","BK1544","IE00BPRC5H50.USD","LU0348767384.USD","LU0828237940.HKD","LU0314109678.HKD","HK0000165453.HKD","SG9999003461.SGD","LU0593848301.USD","LU2279858448.HKD","03115","MCHmain","07300","MHImain","83115","LU0561508036.HKD","BK1592","SG9999001093.SGD","LU1171460220.USD","IE00B5MMRT66.SGD","LU0348825331.USD","LU0348766576.USD","SGXZ62798434.SGD","LU0140636845.USD","09926","LU0417516902.SGD","LU0181495838.USD","02259","LU0348783233.USD","LU1328277881.USD","HK0000500386.USD","LU1242518857.USD","IE00B543WZ88.USD","LU2778985437.USD","LU1794554557.SGD","LU0244354667.USD","BK1161","HSI","LU1831875114.USD","LU0540923850.HKD","LU0348735423.USD","03330"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153938851","title":"港股生物医药股全线大涨，金斯瑞涨超6%，药明康德涨超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1153938851","media":"老虎快讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153938851?lang=zh_cn&edition=full","pubTime":"2026-09-21 10:14","pubTimestamp":1789956879,"startTime":"0","endTime":"0","summary":"港股市场生物医药股全线大涨，其中，复宏汉霖涨超10%，君实生物、康方生物涨超8%，康诺亚-B、诺诚健华涨超7%，荣昌生物、金斯瑞生物科技、药明生物、科伦博泰生物涨超6%，药明康德、泰格医药、药明合联涨超3%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03347","02269","01548","02696","01877","09926","02268","06990","02359","09995","02162","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669136031","title":"生物医药板块盘初普升 复宏汉霖（02696）涨7.96% 机构指中国创新药进入全球价值兑现阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2669136031","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669136031?lang=zh_cn&edition=full","pubTime":"2026-09-21 09:49","pubTimestamp":1789955355,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股生物医药板块盘初普升，截至发稿，复宏汉霖 涨7.96%，诺诚健华涨7.34%，荣昌生物涨6.69%，康诺亚-B涨6.52%，康方生物涨6.46%，君实生物涨6.41%，金斯瑞生物科技涨5.80%，科伦博泰生物涨5.63%，药明生物涨4.47%，药明康德涨2.90%，泰格医药涨2.69%，百济神州涨2.07%，药明合联涨1.75%。中信证券表示，中国创新药进入全球价值兑现阶段，头部国际化创新药企业有望迎来产品全球价值兑现期。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250110/OTZhY2RjY2M0NGRhYmE3MDgxYTI5ZDA4OTNlODY4MjM3MDk5ODc3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/OTZhY2RjY2M0NGRhYmE3MDgxYTI5ZDA4OTNlODY4MjM3MDk5ODc3.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992049","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990","BK1610","LU0320764243.SGD","BK1588","LU0244354667.USD","LU0463099449.HKD","LU0029874905.USD","LU2476274720.SGD","BK4588","03347","LU0052750758.USD","BK1515","LU1188198961.HKD","09995","LU0326950275.SGD","LU0348784397.USD","399441","LU0540923850.HKD","LU0561508036.HKD","LU0979878070.USD","XBI","HK0000165453.HKD","LU1303224171.USD","01877","02696","02162","LU2488822045.USD","02268","LU0456827905.SGD","LU1961090484.USD","KURE","LU0320764599.SGD","LU0327786744.USD","LU0516422952.EUR","LU0348767384.USD","LU0196878994.USD","LU0348766576.USD","01548","LU1880383366.USD","06160","02359","02269","09926","161726","LU2242644610.SGD","LU0634319403.HKD","LU2045819591.USD","09969","LU0128522744.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109320205","title":"异动解读｜科伦博泰生物盘中上涨3.34%，中期业绩扭亏叠加哮喘管线三期启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1109320205","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109320205?lang=zh_cn&edition=full","pubTime":"2026-09-21 09:32","pubTimestamp":1789954371,"startTime":"0","endTime":"0","summary":"9月21日，科伦博泰生物盘中上涨3.34%，报472.8港元，成交额1169.57万港元。消息面上，公司近日发布中期报告，上半年营收9.78亿元，同比增长2.9%；期内利润3.88亿元，同比扭亏为盈，药品销售收入6.57亿元同比大增112%。此外，合作伙伴Windward Bio公布SKB378/WIN378治疗哮喘的二期临床取得阳性结果，并已启动三期研究，采用一年两次给药方案。多家券商随后上调目标价，瑞银升至678港元、交银国际升至642港元，均维持买入评级。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"科伦博泰生物上涨，扭亏叠加哮喘三期启动","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668977592","title":"科伦博泰市值为何反超母公司？","url":"https://stock-news.laohu8.com/highlight/detail?id=2668977592","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668977592?lang=zh_cn&edition=full","pubTime":"2026-09-19 14:11","pubTimestamp":1789798262,"startTime":"0","endTime":"0","summary":"值得注意的是，科伦博泰的核心技术平台、生产产能、核心人才体系均依托母公司赋能搭建，母公司更是手握超半数股权，理论上完全享有创新资产的增值红利。商业化步入正轨，但盈利质量尚待验证科伦博泰2026年上半年的归母净利润为3.88亿元，扣除以权益结算的股份支付后的经调整净利润为4.79亿元，实现上市后首次转正。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1789368221046307034","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["LU1064130708.USD","LU2148510915.USD","LU0196878994.USD","BK1161","06990","LU1979443071.USD","BK0060","LU1934453819.USD","LU1064131003.USD","002422","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164105859","title":"科伦博泰生物2026年上半年营收9.78亿元，经调整净利润4.79亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1164105859","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164105859?lang=zh_cn&edition=full","pubTime":"2026-09-17 21:48","pubTimestamp":1789652897,"startTime":"0","endTime":"0","summary":"科伦博泰生物公布的2026年上半年财报显示，营收达到人民币9.78亿元，同比增长2.9%。毛利7.37亿元，同比增长11.7%，毛利率从上年同期的69.4%升至75.3%。经调整净利润从上年同期的-0.69亿元转为本期的4.79亿元，实现扭亏为盈；经营活动产生的现金流量净额约3.39亿元，上年同期为-3.73亿元。报告期内，药品销售收入达6.57亿元，同比增长112%。财报显示，这一增幅主要得益于多款创新药的集中上市，并持续受到临床医生及市场的认可。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"科伦博泰生物2026年上半年营收9.78亿元，经调整净利润4.79亿元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182852375","title":"科伦博泰生物：汇添富基金管理股份有限公司减持，好仓比例降至4.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=1182852375","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182852375?lang=zh_cn&edition=full","pubTime":"2026-09-16 17:32","pubTimestamp":1789551170,"startTime":"0","endTime":"0","summary":"汇添富基金管理股份有限公司于2026年9月11日在联交所场内以每股均价463.8033港元卖出科伦博泰生物1.51万股，涉资约700.34万港元，属场内主动交易，即在二级市场直接买卖股份。汇添富基金管理股份有限公司此次减持前持有科伦博泰生物好仓884.46万股，占比5.0%；减持后持股量为882.95万股，好仓比例降至4.99%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667658010","title":"港股异动 | 科伦博泰生物(06990)涨超3% POLARIS-1临床试验2期部分取得阳性结果 并已启动3期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2667658010","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667658010?lang=zh_cn&edition=full","pubTime":"2026-09-14 14:36","pubTimestamp":1789367775,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科伦博泰生物涨超3%，截至发稿，涨3.35%，报480.8港元，成交额2.53亿港元。消息面上，近日，科伦博泰生物发布公告，公司的合作方Windward Bio AG已公布SKB378/WIN378用于治疗哮喘的POLARIS-1临床试验2期部分取得阳性的中期结果。POLARIS-1的3期部分已由Windward Bio启动，确定采用两种每年两次给药的剂量方案，旨在评估SKB378/WIN378对重度哮喘患者的年化哮喘急性发作率及其他关键疗效指标的影响。POLARIS-1的2期研究数据将在即将召开的医学会议上公布。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495550.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0196878994.USD","06990","VXUS","BK4585","BK1161","KCAI","MDTX","PSYK","BK4588","BMED","IBBJ","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665320030","title":"科伦博泰生物：POLARIS-1的2期部分取得阳性中期结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320030","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665320030?lang=zh_cn&edition=full","pubTime":"2026-09-08 20:20","pubTimestamp":1788870014,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1161","LU0196878994.USD","06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131010373","title":"科伦博泰生物：TSLP 抗体新药 SKB378/WIN378 哮喘 2 期试验获阳性数据，3 期临床启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1131010373","media":"公告速递","labels":["productRelease","dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131010373?lang=zh_cn&edition=full","pubTime":"2026-09-08 20:11","pubTimestamp":1788869510,"startTime":"0","endTime":"0","summary":"2026年9月8日，科伦博泰生物医药股份有限公司公告称，其合作方 Windward Bio AG 公布的 TSLP 靶向全人源超长效单克隆抗体 SKB378/WIN378 在治疗哮喘的全球无缝 2/3 期临床研究 POLARIS-1中取得阳性 2 期中期结果，并已启动 3 期研究。主要评估皮下注射 SKB378/WIN378 三个剂量与安慰剂的药代动力学、安全性、免疫原性及药效学活性，并为 3 期剂量选择提供依据，同时监测对肺功能及气道炎症生物标志物的影响。公司提醒投资者，SKB378/WIN378 最终不一定能够成功开发及商业化，请投资者注意投资风险。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101577692","title":"科伦博泰生物：Polaris-2三期临床试验第二阶段计划于2027年上半年启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1101577692","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101577692?lang=zh_cn&edition=full","pubTime":"2026-09-08 20:07","pubTimestamp":1788869230,"startTime":"0","endTime":"0","summary":"科伦博泰生物宣布，其Polaris-2三期临床试验的第二阶段计划于2027年上半年正式启动。这一时间表的确定，标志着该公司在药物研发管线上迈出了关键一步。据悉，Polaris-2是科伦博泰生物重点推进的临床项目之一，此次公布的启动计划延续了公司此前披露的研发节奏。需要指出的是，药物研发具有高度不确定性，实际启动时间仍可能受到监管审批、患者入组速度等多重因素影响。因此，后续公告仍然值得持续跟踪。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0196878994.USD","06990","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123875780","title":"科伦博泰生物合作伙伴Windward Bio启动SKB378/WIN378三期临床研究，探索一年两次给药方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1123875780","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123875780?lang=zh_cn&edition=full","pubTime":"2026-09-08 20:07","pubTimestamp":1788869230,"startTime":"0","endTime":"0","summary":"科伦博泰生物（06990.HK）宣布，其合作伙伴Windward Bio已正式启动SKB378/WIN378的三期临床研究。值得注意的是，该研究将重点评估一年两次给药方案的疗效与安全性——这一剂量策略的推进，标志着这款在研药物在给药便利性方面迈出了重要一步。SKB378/WIN378作为一种备受关注的生物制剂，此次三期研究的启动，不仅意味着其临床开发进程进入关键阶段，也为未来可能的患者用药体验改善奠定了基础。Windward Bio方面表示，选择一年两次的给药频率，旨在平衡持续疗效与用药依从性之间的需求。对于科伦博泰生物而言，这一进展也进一步彰显了其管线资产的外部合作价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06990","LU0196878994.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166861904","title":"科伦博泰生物SKB378/WIN378耐受性良好，未出现治疗相关严重不良事件","url":"https://stock-news.laohu8.com/highlight/detail?id=1166861904","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166861904?lang=zh_cn&edition=full","pubTime":"2026-09-08 20:06","pubTimestamp":1788869168,"startTime":"0","endTime":"0","summary":"科伦博泰生物制药股份有限公司近日公布，其研发的SKB378/WIN378药物展现出良好的耐受性。在临床研究中，该药物未引发任何与治疗相关的严重不良事件，这一结果为后续研发工作奠定了坚实基础。安全性数据的积极表现，无疑为这款候选药物注入了更强信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990","LU0196878994.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://kelun-biotech.com","stockEarnings":[{"period":"1week","weight":-0.0351},{"period":"1month","weight":-0.0807},{"period":"3month","weight":0.0844},{"period":"6month","weight":-0.0606},{"period":"1year","weight":-0.0456},{"period":"ytd","weight":0.206}],"compareEarnings":[{"period":"1week","weight":-0.0225},{"period":"1month","weight":-0.0415},{"period":"3month","weight":0.0718},{"period":"6month","weight":-0.0236},{"period":"1year","weight":-0.0789},{"period":"ytd","weight":-0.0432}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"四川科伦博泰生物医药股份有限公司是一家主要从事新药业务的研发、生产和销售的中国公司。该公司主要从事肿瘤学、免疫学及其他治疗领域的创新药物的研发、制造及商业化。该公司的产品有抗体药物偶联物（ADC）SKB264和A166等。该公司产品主要用于乳腺癌、非小细胞肺癌、胃肠道癌等疾病的治疗。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.05939},{"month":2,"riseRate":0.666667,"avgChangeRate":0.239909},{"month":3,"riseRate":1,"avgChangeRate":0.292496},{"month":4,"riseRate":1,"avgChangeRate":0.083557},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.011152},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.022649},{"month":7,"riseRate":0.666667,"avgChangeRate":0.111158},{"month":8,"riseRate":1,"avgChangeRate":0.042518},{"month":9,"riseRate":0.75,"avgChangeRate":0.051409},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.03489},{"month":11,"riseRate":1,"avgChangeRate":0.072292},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.053467}],"exchange":"SEHK","name":"科伦博泰生物","nameEN":"SKB BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"科伦博泰生物(06990)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供科伦博泰生物(06990)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"科伦博泰生物,06990,科伦博泰生物股票,科伦博泰生物股票老虎,科伦博泰生物股票老虎国际,科伦博泰生物行情,科伦博泰生物股票行情,科伦博泰生物股价,科伦博泰生物股市,科伦博泰生物股票价格,科伦博泰生物股票交易,科伦博泰生物股票购买,科伦博泰生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"科伦博泰生物(06990)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供科伦博泰生物(06990)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}